Amur Minerals Corporation Investor Presentation via Investor Meet Company

RNS Number : 4433O

Amur Minerals Corporation

15 May 2024

 

15 May 2024

 

AMUR MINERALS CORPORATION

(AIM: AMC)

 

Investor Presentation via Investor Meet Company

 

Amur Minerals Corporation ("Amur" or the "Company") is pleased to announce that Robin Young, CEO of Amur, and Andrew Webb, CEO of Extruded Pharmaceuticals Limited ("Extruded Pharmaceuticals" or "EPL"), will provide a live presentation on 21 May 2024 at 1pm BST via the Investor Meet Company platform.

 

The presentation will focus on the proposed acquisition of EPL by Amur and all existing and potential shareholders are welcome to participate. Questions can be submitted in advance of the presentation via the Investor Meet Company dashboard up until 20 May 2024 at 9am BST and also at any time during the live presentation.

 

Investors who are not already signed up to Investor Meet Company can sign up here:

https://www.investormeetcompany.com/amur-minerals-corporation/register-investor

 

Investors who already follow Amur on the Investor Meet Company platform will automatically be invited.

 

On the 13 May 2024, Amur announced its intention to acquire EPL, a UK-based drug delivery technology company which is focused on improving the performance of cancer treatments for solid tumours through the local delivery of chemotherapy drugs. The announcement can be viewed here: https://www.londonstockexchange.com/news-article/AMC/proposed-reverse-takeover/16465616

 

The acquisition is subject to a General Meeting of Amur shareholders on 29 May 2024.

 

 

Enquiries:

 

Company	Nomad and Broker	Financial PR
Amur Minerals Corp.	S.P. Angel Corporate Finance LLP	Buchanan
Robin Young CEO	Richard Morrison Adam Cowl	Mark Court [e-mail] Jamie Hooper [e-mail]
[phone]	[phone]	[phone]

 

 

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [e-mail] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

 

END

 

 

MSCBIGDULXBDGSS